Business
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity in FranceAn increase in Q3 of 2.6% at CER and on a like-for-like basis, underpinned by the acceleration of EluciremTM sales and good momentum on Lipiodol® Confirmation of all financial targets for 2025 Villepinte, October 23, 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions
About this update from Guerbet Sa
[{"type":"image","alt":"GUERBET","displaySize":"","headline":null,"caption":"GUERBET","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/3975ab9f5076034731af8ca99ee4b169"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XW0Ga4G5pYagH_4N.1hQ2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3975ab9f5076034731af8ca99ee4b169","width":300,"height":105}},"lazy":false},{"type":"text","content":"Revenue at September 30, 2025","length":29,"tagName":"p"},{"type":"text","content":"Return to growth in Q3 2025","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"9-month revenue: €586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity in France","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"An increase in Q3 of 2.6% at CER and on a like-for-like basis, underpinned by the acceleration of EluciremTM sales and good momentum on Lipiodol®","length":145,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":272,"olType":false},{"type":"text","content":"Confirmation of all financial targets for 2025","length":46,"tagName":"p"},{"type":"text","content":"Villepinte, October 23, 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for the first nine months of 2025.","length":203,"tagName":"p"},{"type":"text","content":"At September 30, 2025, Group sales totaled €586.5 million, representing a decrease of 5.5%. At constant exchange rates (CER)1, sales fell by 3.1%, incorporating a negative foreign exchange effect of €14.6 million, mainly due to the depreciation of the currencies of Latin America and Asia. At CER and on a like-for-like basis2, sales decreased by 2.8%.","length":352,"tagName":"p"},{"type":"text","content":"This reflects a steady sequential improvement throughout the year: after falling by 7.1% in the first quarter and 3.9% in the second quarter, Guerbet saw a resumption of growth in the third quarter to +2.6% at CER and on a like-for-like basis. This acceleration, which is in line with the Group’s forecast, is expected to continue in the fourth quarter of 2025.","length":361,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"va...